期刊文献+

174株鲍曼/醋酸钙不动杆菌复合体临床分布及耐药性分析 被引量:2

Analysis of Clinical Distribution and Antibiotic Resistance of 174 Strains of A. calcoaceticus-A. baumannii complex
下载PDF
导出
摘要 目的了解鲍曼/醋酸钙不动杆菌复合体(A.calcoaceticus-A.baumannii complex,ACB complex)在笔者医院各临床科室的分布情况及其耐药性,为临床合理使用抗菌药物提供依据。方法所有菌株均采用VITEK2-compact全自动微生物分析仪进行菌种鉴定及药敏分析。结果 174株ACB complex主要来源于ICU病区(53.5%),其次为成人外科病区(24.1%)和儿科病区(12.1%)。标本类型主要为痰液(81.2%)、血液(占5.2%)、创口渗出物(占4.0%)等。ACB complex对呋喃妥因、头孢唑林耐药率最高,达100%,而对头孢哌酮/舒巴坦的耐药率仅为1.2%。此外,本研究资料显示,耐亚胺培南ACB complex均为多重耐药菌株,约占所有菌株的46%。其中分离于成人患者的ACB complex对亚胺培南的耐药率为62.9%,而新生儿及儿童的ACB complex对其耐药率分别为6.7%和14%。结论笔者医院ACB complex主要分布于ICU病区,且耐药率高。多重耐药ACB complex已出现于儿科病区,应引起临床医师的足够重视,定期监测ACB complex临床分布和耐药情况,可为临床合理使用抗菌药物提供依据。 Objective To investigate the distribution and drug sensitivity instance of A. calcoaceticus - A. baumannii complex in Yuying Children's Hospital Affiliated to Wenzhou Medical University, so as to prevent and control the nosocomial infections. Methods Isolates of A. calcoaceticus - A. baumannii complex were collected between November 2012 and May 2013 in our hospital. The data were analyzed by WHONET 5.6 software. Results A total of 174 strains of A. calcoaceticus - A. baumannii complex were analyzed, of which 142(81.2% ) were isolated from sputum, 9(5.2% ) from blood, 7(4.0% ) from wound. Most of the strains were isolated from the fol- lowing departments : ICU ( 93,53.5 % ), surgical department ( 42,24.1% ) and pediatrics department ( 21,12.1% ). The antimicrobial sus- ceptibility testing revealed that the lowest resistance rate of A. calcoaceticus - A. baumannii was 1.2% to cefoperazone - sulbactam, and highest 100% to macrodantin and cefazolin. About 46% of these A. calcoaceticus - A. baumannii strains were resistant to imipenem. Conclusion Clinical A. calcoaceticus - A. baumannii are mainly isolated from sputum, most of which were from ICU. The supervision of the reasonable application of antimicrobial drugs should be strengthened, and nosocomial infections should be controlled to ensure medical safety.
出处 《医学研究杂志》 2013年第12期94-97,共4页 Journal of Medical Research
关键词 鲍曼 醋酸钙不动杆菌复合体耐药性 抗菌药物 A. calcoaceticus - A. baumannii Antibacterial Drug resistance
  • 相关文献

参考文献14

  • 1O'Shea MK.Acinetobacter in modern warfare[J].International Journal of Antimicrobial Agents.2012,39 (5):363-375.
  • 2陈佰义,何礼贤,胡必杰,倪语星,邱海波,石岩,施毅,王辉,王明贵,杨毅,张菁,俞云松.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85. 被引量:844
  • 3Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii:emergence of a successful pathogen[J].Clinical Microbiology Reviews,2008,21 (3):538-582.
  • 4Lai CC,Hsu HL,Tan CK,et al.Recurrent bacteremia caused by the Acinetobacter calcoaceticus-Acinetobacter baumannii complex[J].Journal of Clinical Microbiology,2012,50 (9):2982-2986.
  • 5Lee K,Yong D,Jeong SH,et al.Multidrug-resistant Acinetobacter spp.:increasingly problematic nosocomial pathogens[J].Yonsei Medical Journal,2011,52 (6):879-891.
  • 6Duenas Diez AI,Bratos Perez MA,Eiros Bouza JM,et al.Susceptibility of the Acinetobacter calcoaceticus-A.baumannii complex to imipenem,meropenem,sulbactam and colistin[J].International Journal of Antimicrobial Agents,2004,23 (5):487-493.
  • 7俞云松.多药耐药鲍曼不动杆菌——21世纪革兰阴性菌的“MRSA”[J].中华临床感染病杂志,2009,2(2):65-68. 被引量:93
  • 8张丽红,王宏斌.鲍曼不动杆菌的临床分布及耐药性分析[J].医学研究杂志,2012,41(1):145-147. 被引量:2
  • 9Lin MF,Yang CM,Lin CH,et al.Clinical features and molecular epidemiology of multidrug-resistant Acinetobacter calcoaceticus-A baumannii complex in a regional teaching hospital in Taiwan[J].American Journal of Infection Control,2009,37(9):e1-e3.
  • 10Yamada K,Yanagihara K,Araki N,et al.Clinical characteristics of tertiary hospital Patients from whom acinetobacter calcoaceticus-acinetobacter baumannii complex strains were isolated[J].Internal Medicine,2012,51 (1):51-57.

二级参考文献22

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:239
  • 2李苏利,李杨,华川.多重耐药鲍氏不动杆菌耐药现状与临床对策[J].中华医院感染学杂志,2005,15(12):1438-1440. 被引量:102
  • 3郭玲娇,李招云,张颖,陈贤君.鲍氏不动杆菌感染及耐药性分析[J].中华医院感染学杂志,2007,17(2):216-217. 被引量:35
  • 4Karageorgopoulos DE,Falagas ME.Current control and treatment of multidrug-resistant acinetobacter baumannii infections[J].Lancet Infect Dis,2008,8:7512-7762.
  • 5Poirel L,Nordmann P.Carbapenem resistance in Acinetobacter baumannii:mechanisms and epidemiology.[J].Clin Microbiol Infect,2006,12:826-836.
  • 6Thapa B,Tribuddharat C,Srifuengfung S,et al.High prevalence of bla(OXA)-23 in oligoclonal carbapenem-resistant Acinetobacter baumannii from Siriraj Hospital,Mahidol University,Bangkok,Thailand.[J].Southeast Asian J Trop M ed Public Health,2010,41 (3):625-635.
  • 7Nordmann P.Gram-negative bacteriae with resistance to carbapenems[J].Med Sci,2010,26(11):950-959.
  • 8Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J]. N Engl J Med, 2009, 360(5) : 439-443.
  • 9Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Tweenty-first in- formational supplement, 2011, M100-S21 Vol 31 No. 1.
  • 10Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfo- mycin: use beyond urinary tract and gastrointestinal infec tions[J]. Clin Infect Dis, 2008, 46(7): 1069-1077.

共引文献1419

同被引文献10

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部